incretin mimetics glp 1 agonists - an overview Incretins: How we got here,

We could expect from early treatment with oral semaglutide and other GLP-1 analogues a better control of cardiovascular risks as a result of its actions exerted before atherosclerosis develops, in addition to the benefits of superior glucose control and weight loss

By 2030, the market is set to reach $33.26 billion, maintaining a CAGR of 8.6%

Although attention shifted after insulin was discovered, the mystery of the guts role in glucose regulation refused to die

32 A meta-analysis of over 76 clinical trials that investigated the efficacy of 15 different types of GLP-1RAs revealed that all 15 of the drugs were highly effective at treating T2D

Fasting plasma glucose decreased by 16.2 mg/dL, compared to 9.0 mg/dL with placebo